2.68
+0(+0.00%)
Currency In USD
Address
930 Winter Street
Waltham, MA 02116
United States of America
Phone
617 443 2400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
June 30, 2021
| Name | Title | Pay | Year Born |
| Mr. Timothy P. Noyes M.B.A. | Chief Executive Officer & Director | 936,899 | 1962 |
| Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer | 372,333 | 1960 |
| Dr. Benjamin T. Dake Ph.D. | Founder, President, Chief Operating Officer & Secretary | 435,500 | 1976 |
| Mr. Hunter Gillies M.D. | Chief Medical Officer | 512,742 | 1966 |
| Mr. George A. Eldridge | Chief Financial Officer & Treasurer | 658,600 | 1963 |
| Ms. Susan Fischer | Executive Vice President of Development Operations | 0 | N/A |
| Mr. Stephen K. Yu | Senior Vice President of Quality | 0 | N/A |
| Ms. Donna Dea | Head of Regulatory Affairs | 0 | N/A |
| Dr. Sanjeev Khindri | Executive Vice President of Clinical Development | 0 | N/A |
| Dr. Cheryl Lassen BSc., M.D., MBBCh | Senior Vice President of Clinical Development | 0 | N/A |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.